Literature DB >> 27789677

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Dominik Selleslag1, Stefan Suciu2, Giovanna Meloni3, Petra Muus4, Constantijn J M Halkes5, Adriano Venditti6, Safaa M Ramadan2,7, Hans Pruijt8, Liv Meert2, Marco Vignetti9, Jean-Pierre Marie10, Sébastian Wittnebel11, Theo de Witte12, Sergio Amadori6, Roelof Willemze5, Frédéric Baron13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27789677      PMCID： PMC5286953          DOI： 10.3324/haematol.2016.153130

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Authors:  J Versluis; F E M In 't Hout; R Devillier; W L J van Putten; M G Manz; M-C Vekemans; M-C Legdeur; J R Passweg; J Maertens; J Kuball; B J Biemond; P J M Valk; B A van der Reijden; G Meloni; H C Schouten; E Vellenga; T Pabst; R Willemze; B Löwenberg; G Ossenkoppele; F Baron; G Huls; J J Cornelissen
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

2.  European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

Authors:  Alan K Burnett; Nigel H Russell; Jonathan Kell; Michael Dennis; Donald Milligan; Stefania Paolini; John Yin; Dominic Culligan; Peter Johnston; John Murphy; Mary-Frances McMullin; Ann Hunter; Emma Das-Gupta; Richard Clark; Robert Carr; Robert K Hills
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

Authors:  Pamela S Becker; Bruno C Medeiros; Anthony S Stein; Megan Othus; Frederick R Appelbaum; Stephen J Forman; Bart L Scott; Paul C Hendrie; Kelda M Gardner; John M Pagel; Roland B Walter; Cynthia Parks; Brent L Wood; Janis L Abkowitz; Elihu H Estey
Journal:  Am J Hematol       Date:  2015-01-30       Impact factor: 10.047

4.  High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Authors:  Roelof Willemze; Stefan Suciu; Giovanna Meloni; Boris Labar; Jean-Pierre Marie; Constantijn J M Halkes; Petra Muus; Martin Mistrik; Sergio Amadori; Giorgina Specchia; Francesco Fabbiano; Francesco Nobile; Marco Sborgia; Andrea Camera; Dominik L D Selleslag; Francois Lefrère; Domenico Magro; Simona Sica; Nicola Cantore; Meral Beksac; Zwi Berneman; Xavier Thomas; Lorella Melillo; Jose E Guimaraes; Pietro Leoni; Mario Luppi; Maria E Mitra; Dominique Bron; Georges Fillet; Erik W A Marijt; Adriano Venditti; Anne Hagemeijer; Marco Mancini; Joop Jansen; Daniela Cilloni; Liv Meert; Paola Fazi; Marco Vignetti; Silvia M Trisolini; Franco Mandelli; Theo de Witte
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

6.  Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Authors:  Aziz Nazha; Hagop Kantarjian; Farhad Ravandi; Xuelin Huang; Sangbum Choi; Guillermo Garcia-Manero; Elias Jabbour; Gautam Borthakur; Tapan Kadia; Marina Konopleva; Jorge Cortes; Alessandra Ferrajoli; Steve Kornblau; Naval Daver; Naveen Pemmaraju; Michael Andreeff; Zeev Estrov; Min Du; Mark Brandt; Stefan Faderl
Journal:  Am J Hematol       Date:  2013-09-09       Impact factor: 10.047

7.  Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

Authors:  Franco Mandelli; Marco Vignetti; Stefan Suciu; Roberto Stasi; Maria-Concetta Petti; Giovanna Meloni; Petra Muus; Filippo Marmont; Jean-Pierre Marie; Boris Labar; Xavier Thomas; Francesco Di Raimondo; Roel Willemze; Vincenzo Liso; Felicetto Ferrara; Liliana Baila; Paola Fazi; Robert Zittoun; Sergio Amadori; Theo de Witte
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Authors:  Stefan Faderl; Meir Wetzler; David Rizzieri; Gary Schiller; Madan Jagasia; Robert Stuart; Siddhartha Ganguly; David Avigan; Michael Craig; Robert Collins; Michael Maris; Tibor Kovacsovics; Stuart Goldberg; Karen Seiter; Parameswaran Hari; Jochen Greiner; Norbert Vey; Christian Recher; Farhad Ravandi; Eunice S Wang; Michael Vasconcelles; Dirk Huebner; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

Review 9.  The role of clofarabine in acute myeloid leukemia.

Authors:  Hady Ghanem; Hagop Kantarjian; Maro Ohanian; Elias Jabbour
Journal:  Leuk Lymphoma       Date:  2012-09-28

10.  Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

Authors:  R B Walter; M Othus; A K Burnett; B Löwenberg; H M Kantarjian; G J Ossenkoppele; R K Hills; F Ravandi; T Pabst; A Evans; S R Pierce; M-C Vekemans; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2014-08-12       Impact factor: 11.528
View more
  1 in total

1.  Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.

Authors:  Harinder Gill; Rita Yim; Herbert H Pang; Paul Lee; Thomas S Y Chan; Yu-Yan Hwang; Garret M K Leung; Ho-Wan Ip; Rock Y Y Leung; Sze-Fai Yip; Bonnie Kho; Harold K K Lee; Vivien Mak; Chi-Chung Chan; June S M Lau; Chi-Kuen Lau; Shek-Yin Lin; Raymond S M Wong; Wa Li; Edmond S K Ma; Jun Li; Gianni Panagiotou; Joycelyn P Y Sim; Albert K W Lie; Yok-Lam Kwong
Journal:  Cancer Med       Date:  2020-03-18       Impact factor: 4.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.